DNA-Tester 23andMe Starts Trial of First Drug Developed In-House
- Immuno-oncology antibody aimed at treatment of solid tumors
- Best known for its genetic tests, 23andMe is moving into drugs
This article is for subscribers only.
DNA-testing giant 23andMe Holding Co. began clinical trials this week of its first drug developed entirely in-house, a critical step toward the company’s ambitions to make and sell its own therapies.
The drug, dubbed 23ME-00610 for now, is an immuno-oncology antibody aimed at treating solid tumors. The first patient in the therapy’s Phase I clinical trials received their first dose this week.